BGB-43395

BGB-43395 is a small-molecule drug developed by BeOne Medicines. The sponsor describes its target as CDK4, which OnCo does not yet have a target page for. The sponsor states: A CDK4-selective inhibitor designed to spare CDK6, intended to drive down cancer cell growth signalling while reducing the blood-cell toxicities associated with CDK6 inhibition. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07492641 (BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease), in HR-positive / HER2-negative breast cancer. The largest, NCT07492641, plans to enrol 1056 participants with primary completion expected 2029-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.